Acute kidney injury in patients with COVID-19: a retrospective cohort study from Switzerland

被引:15
作者
Diebold, Matthias [1 ]
Schaub, Stefan [1 ]
Landmann, Emmanuelle [1 ]
Steiger, Jurg [1 ]
Dickenmann, Michael [1 ]
机构
[1] Univ Hosp Basel, Clin Transplantat Immunol & Nephrol, CH-4031 Basel, Switzerland
关键词
acute kidney injury; COVID-19; SARS-CoV2;
D O I
10.4414/smw.2021.20482
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BACKGROUND: Data about patients in Europe with corona virus disease-2019 (COVID-19) and acute kidney injury (AKI) are scarce. We examined characteristics, presentation and risk factors of AKI in patients hospitalised with COVID-19 in a tertiary hospital in Switzerland. METHODS: We reviewed health records of patients hospitalised with a positive nasopharyngeal polymerase chain reaction test for SARS-CoV2 between 1 February and 30 June 2020, at the University Hospital of Basel. The nadir creatinine of the hospitalisation was used as baseline. AKI was defined according the KDIGO guidelines as a 1.5x increase of baseline creatinine and in-hospital renal recovery as a discharge creatinine <1.25x baseline creatinine. Least absolute shrinkage and selection operator (LASSO) regression was performed to select predictive variables of AKI. Based on this a final model was chosen. RESULTS: Of 188 patients with COVID-19, 41 (22%) developed AKI, and 11 (6%) required renal replacement therapy. AKI developed after a median of 9 days (interquartile range [IQR] 5-12) after the first symptoms and a median of 1 day (IQR 0-5) after hospital admission. The peak AKI stages were stage 1 in 39%, stage 2 in 24% and stage 3 in 37%. A total of 29 (15%) patients were admitted to the intensive care unit and of these 23 (79%) developed AKI. In-hospital renal recovery at discharge was observed in 61% of all AKI episodes. In-hospital mortality was 27% in patients with AKI and 10% in patients without AKI. Age (adjusted odds ratio [aOR] 1.04, 95% confidence interval [CI] 1.01-1.08; p = 0.024), history of chronic kidney disease (aOR 3.47, 95% CI 1.16-10.49;p = 0.026), C-reactive protein levels (aOR 1.09, 95% CI 1.03-1.06; p = 0.002) and creatinine kinase (aOR 1.03, 95% CI 1.01-1.06; p = 0.002) were associated with development of AKI. CONCLUSIONS: AKI is common in hospitalised patients with COVID-19 and more often seen in patients with severe COVID-19 illness. AKI is associated with a high in-hospital mortality.
引用
收藏
页数:9
相关论文
共 26 条
[1]  
Beretta A., 2020, SWISS MED WEEKLY, V150
[2]  
Chan Lili, 2020, medRxiv, DOI 10.1101/2020.05.04.20090944
[3]   Characteristics, comorbidities, 30-day outcome and in-hospital mortality of patients hospitalised with COVID-19 in a Swiss area - a retrospective cohort study [J].
Charlotte, Pellaud ;
Gael, Grandmaison ;
Huua, Thien Hoa Phong Pham ;
Marine, Baumberger ;
Guillaume, Carrel ;
Hatem, Ksouri ;
Veronique, Erard ;
Christian, Chuard ;
Daniels, Hayoz ;
Govind, Sridharan .
SWISS MEDICAL WEEKLY, 2020, 150
[4]   The Incidence, Risk Factors, and Prognosis of Acute Kidney Injury in Adult Patients with Coronavirus Disease 2019 [J].
Cheng, Yichun ;
Luo, Ran ;
Wang, Xu ;
Wang, Kun ;
Zhang, Nanhui ;
Zhang, Meng ;
Wang, Zhixiang ;
Dong, Lei ;
Li, Junhua ;
Zeng, Rui ;
Yao, Ying ;
Ge, Shuwang ;
Xu, Gang .
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2020, 15 (10) :1394-1402
[5]  
Cheng YC, 2020, KIDNEY INT, V97, P829, DOI 10.1016/j.kint.2020.03.005
[6]  
Diao B, HUMAN KIDNEY IS TARG, DOI [10.1016/j.kint.2020.05.006, DOI 10.1016/J.KINT.2020.05.006]
[7]   Foreword [J].
Eckardt, Kai-Uwe ;
Kasiske, Bertram L. .
KIDNEY INTERNATIONAL SUPPLEMENTS, 2012, 2 (01) :7-7
[8]   COVACTA trial raises questions about tocilizumab's benefit in COVID-19 [J].
Furlow, Bryant .
LANCET RHEUMATOLOGY, 2020, 2 (10) :E592-E592
[9]  
Guan WJ, 2020, NEW ENGL J MED, V382, P1861, DOI 10.1056/NEJMc2005203
[10]   Urinary Sediment Microscopy in Acute Kidney Injury Associated with COVID-19 [J].
Hernandez-Arroyo, Cesar F. ;
Varghese, Vipin ;
Mohamed, Muner M. B. ;
Velez, Juan Carlos Q. .
KIDNEY360, 2020, 1 (08) :819-823